WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H522377
CAS#: 1165910-22-4
Description: Ligandrol, also known as VK5211, LGD-4033, is a novel nonsteroidal oral selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, LGD-4033 is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, currently under development by Ligand Pharmaceuticals. LGD-4033 was safe, had favorable pharmacokinetic profile.
Hodoodo Cat#: H522377
Name: Ligandrol
CAS#: 1165910-22-4
Chemical Formula: C14H12F6N2O
Exact Mass: 338.09
Molecular Weight: 338.250
Elemental Analysis: C, 49.71; H, 3.58; F, 33.70; N, 8.28; O, 4.73
Synonym: LGD-4033; LGD 4033; LGD4033; VK5211; VK-5211; VK 5211; Ligandrol.
IUPAC/Chemical Name: 4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-(trifluoromethyl)benzonitrile
InChi Key: OPSIVAKKLQRWKC-VXGBXAGGSA-N
InChi Code: InChI=1S/C14H12F6N2O/c15-13(16,17)10-6-9(4-3-8(10)7-21)22-5-1-2-11(22)12(23)14(18,19)20/h3-4,6,11-12,23H,1-2,5H2/t11-,12-/m1/s1
SMILES Code: N#CC1=CC=C(N2[C@@H]([C@@H](O)C(F)(F)F)CCC2)C=C1C(F)(F)F
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 338.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Thevis M, Lagojda A, Kuehne D, Thomas A, Dib J, Hansson A, Hedeland M, Bondesson U, Wigger T, Karst U, Schänzer W. Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing. Rapid Commun Mass Spectrom. 2015 Jun 15;29(11):991-9. doi: 10.1002/rcm.7189. PubMed PMID: 26044265.
2: Krug O, Thomas A, Walpurgis K, Piper T, Sigmund G, Schänzer W, Laussmann T, Thevis M. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol. 2014 Nov;70(11):1303-11. doi: 10.1007/s00228-014-1743-5. Epub 2014 Aug 30. PubMed PMID: 25168622.
3: Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013 Dec;7(4):345-51. doi: 10.1097/SPC.0000000000000015. Review. PubMed PMID: 24189892.
4: Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon G, Kazmi S, Sheffield-Moore M, Bhasin S. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95. doi: 10.1093/gerona/gls078. Epub 2012 Mar 28. PubMed PMID: 22459616; PubMed Central PMCID: PMC4111291.